On Oct. 2, 2023, the California Institute for Regenerative Medicine (CIRM) announced its approval of a new program called ReMIND at the September Independent Citizens’ Oversight Committee (ICOC) meeting that will eventually award up to $110 million to advance basic research in neuropsychiatric diseases-one of the largest investments of its kind in California.

ReMIND (Research using Multidisciplinary, Innovative Approaches in Neuro Diseases) is a new program designed to accelerate research innovations that would improve the understanding of the biology of neuropsychiatric diseases using stem cell  or genetic research as its primary approach. The program includes two distinct and separate funding opportunities: the first, ReMIND-L supports large collaborative multidisciplinary projects, and the second, ReMIND-X supports exploratory, high risk, high reward projects. The program will fund research at academic, non-profit, and for-profit organizations in California from 2024 to 2028.

ReMIND was primarily developed in view of Proposition 14, which dedicates at least $1.5 billion of CIRM’s $5.5 billion total bond funding to the support of research and development of treatments for diseases and conditions of the brain and central nervous system.